Skip Navigation


JAC Advance Access originally published online on April 14, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/5/1079    most recent
dkg205v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by De Clercq, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Clercq, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 1079-1083
© 2003 The British Society for Antimicrobial Chemotherapy

Leading Article

New inhibitors of human cytomegalovirus (HCMV) on the horizon

Erik De Clercq*

Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium

Keywords: human cytomegalovirus, antivirals

The first 150 words of the full text of this article appear below.

There are at present five compounds that have been officially licensed for the treatment of human cytomegalovirus (HCMV) infections: ganciclovir [GCV, 9-(1,3-dihydroxy- 2-propoxymethyl)guanine, Cymevene, Cytovene] (1; Figure 1), which is administered intravenously at 10 mg/kg per day (2 x 5 mg/kg, every 12 h) for induction therapy and intravenously at 5 mg/kg once daily or orally at 3000 mg/day (3 x 4 x 250 mg capsules) for maintenance therapy (the latter also for prevention); ganciclovir can also be implanted intravitreally (Vitrasert); foscarnet [trisodium phosphonoformate, phosphonoformic acid (PFA), Foscavir] (2), which is administered intravenously at 180 mg/kg per day (3 x 60 mg/kg, every 8 h) for induction therapy and at 120 mg/kg per day (3 x 40 mg/kg, every 8 h) for maintenance therapy; cidofovir [CDV, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, Vistide] (3), which is administered intravenously at 5 mg/kg per week during the first . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
E. P. Tchesnokov, A. Obikhod, R. F. Schinazi, and M. Gotte
Engineering of a Chimeric RB69 DNA Polymerase Sensitive to Drugs Targeting the Cytomegalovirus Enzyme
J. Biol. Chem., September 25, 2009; 284(39): 26439 - 26446.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Y. Fukui, K. Shindoh, Y. Yamamoto, S. Koyano, I. Kosugi, T. Yamaguchi, I. Kurane, and N. Inoue
Establishment of a Cell-Based Assay for Screening of Compounds Inhibiting Very Early Events in the Cytomegalovirus Replication Cycle and Characterization of a Compound Identified Using the Assay
Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2420 - 2427.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
E. J. Brignole and W. Gibson
Enzymatic Activities of Human Cytomegalovirus Maturational Protease Assemblin and Its Precursor (pPR, pUL80a): Maximal Activity of pPR Requires Self-Interaction through Its Scaffolding Domain
J. Virol., April 15, 2007; 81(8): 4091 - 4103.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
V. Cottier, A. Barberis, and U. Luthi
Novel Yeast Cell-Based Assay To Screen for Inhibitors of Human Cytomegalovirus Protease in a High-Throughput Format
Antimicrob. Agents Chemother., February 1, 2006; 50(2): 565 - 571.
[Abstract] [Full Text] [PDF]